Annual Report and Financial Statements 2024-25
Cure Parkinson's 2024-25 annual report marks the charity's 20th year, covering a transformative period in its research funding. Highlights include a £5.7m commitment to EJS ACT-PD — the UK's first multi-arm multi-stage Parkinson's trial platform — and the opening of recruitment for the ASPro-PD phase 3 ambroxol trial. Nine new projects were funded across clinical, preclinical and observational research, with cumulative research investment now exceeding £25.4m. Reserves grew to £10.8m for the first time, giving the charity the financial agility to lead on larger, more ambitious programmes. The charity aims to raise and invest a further £20m over the next three years.
Report snapshot
£8.1m committed to new research projects; 32 active projects worth £18.5m; cumulative research funding exceeds £25.4m since 2005
Key Metric 1
Cure Parkinson's is a UK charity founded in 2005, now in its 20th year, with a singular focus on funding research to slow, stop and reverse Parkinson's. Around 166,000 people in the UK and an estimated 11.8 million globally live with the condition. The charity funds and facilitates research across clinical trials, preclinical studies and drug discovery, working collaboratively with international partners and academic institutions.
Key Metric 2
Disease-Modifying Research; Clinical Trials; Drug Repurposing; International Collaboration; Policy & Advocacy
Key Metric 3
7
Views